Treatment of MDS Refractory to Hypomethylating Agent
Published Online: Monday, April 21, 2014
For High-Definition, ClickFew treatment options exist for patients with myelodysplastic syndromes (MDS) who progress on hypomethylating agents, such as azacitidine and decitabine. In this setting, for patients with high-risk MDS, the median survival is 4 to 6 months, states Elias J. Jabbour, MD. The best option at this point is a clinical trial.
For patients with low-risk MDS, the median survival for patients following progression on hypomethylating agents is nearly 17 months, Jabbour states. Moreover, the rate of transformation to acute myeloid leukemia is low. In this setting, the most effective options appear to be bone marrow transplant or a clinical trial, adds Rami S. Komrokji, MD.
Numerous clinical studies have examined commercially available agents and combinations following progression, notes Ruben A. Mesa, MD. However, none of these data have transformed the standard of care, since it is unclear if one combination is superior to another. Moreover, none of the trials have resulted in FDA approval.
A clinical trial following progression on hypomethylating agents is the clear favorite of the panel. Unfortunately, access to trials is not always feasible, particularly in the community setting, adds Harry P. Erba, MD, PhD. This fact places more importance on rapidly discovering an optimal and widely available approach.
View More From This Discussion
Mark J. Levis, MD, PhDDirector, Adult Leukemia Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland
Elias J. Jabbour, MDAssociate Professor,
Department of Leukemia,
Division of Cancer Medicine,
MD Anderson Cancer Center, Houston, Texas
Rami S. Komrokji, MDClinical Director, Associate Member, Department of Malignant Hematology
H Lee Moffitt Cancer Center
Ruben A. Mesa, MDChair, Division of Hematology
& Medical Oncology, Mayo Clinic, Scottsdale, Arizona
Rafael Bejar, MD, PhDAssistant Professor of Medicine, Division of Hematology-Oncology
University of California, San Diego, La Jolla, California
Online CME Activities
Most Popular Right Now
The content contained in this video is for general information purposes only. The viewer is encouraged to confirm the information presented with other sources. OncLiveTV Peer Exchange makes no representations or warranties of any kind about the completeness, accuracy, timeliness, reliability, or suitability of any of the information, including content or advertisements, contained in this video and expressly disclaims liability for any errors and omissions that may be presented in this video. OncLiveTV Peer Exchange reserves the right to alter or correct any error or omission in the information it provides in this video, without any obligations. OncLiveTV Peer Exchange further disclaims any and all liability for any direct, indirect, consequential, special, exemplary, or other damages arising from the use or misuse of any material or information presented in this video. The views expressed in this video are those of the panelists and do not necessarily reflect the opinion or policy of OncLiveTV Peer Exchange.